AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Lorlatinib Induced Severe Refractory Hyperlipidemia: A Cardio-Oncology Challenge in ALK Positive NSCLC
By Sarangi S, Coombes K, Saravanabavanandan R et al.
Introduction: Lorlatinib, an ALK tyrosine kinase inhibitor, demonstrated 60% progression-free survival at 5 years in ALK positive NSCLC in the CROWN trial. Grade 3-4 hypercholesterolemia and hypertriglyceridemia occur in 18-19% of patients within a median 15 day onset, with 83% requiring lipid-lowering therapy. Real world data show 79% fail to normalize lipids despite treatment, with increased cerebrovascular risk (OR 5.8 for stroke/TIA). We present lorlatinib induced severe hyperlipidemia managed with triple-agent lipid-lowering therapy. Clinical Timeline: A 61-year-old female diagnosed in 2012 with ALK-rearranged right lower lobe NSCLC underwent lobectomy and adjuvant carboplatin/pemetrexed. She developed extensive intracranial metastases by 2015 despite sequential crizotinib, alectinib, and stereotactic radiosurgery. Following diffuse intracranial progression in October 2023, she transitioned to fourth-line lorlatinib. Within three months, total cholesterol rose from 270 to 411, LDL from 170 to 303, and triglycerides from 162 to 264 mg/dL despite rosuvastatin 40 mg, accompanied by 7 kg weight gain. Echocardiography revealed new global left ventricular hypokinesis, compounding cardiovascular risk. Therapeutic Intervention, Follow Up and Outcomes: Lorlatinib was continued given excellent CNS penetration. Rosuvastatin 40 mg, ezetimibe 10 mg, and evolocumab 140 mg biweekly achieved total cholesterol 222, LDL 108 (64% reduction), and triglycerides 165 mg/dL. Brain MRI in March 2025 showed stable disease. Discussion and Synthesis: This case demonstrates successful management of lorlatinib-induced hyperlipidemia refractory to high-intensity statin monotherapy. Real-world data confirm that only 4% of patients receive PCSK9 inhibitors despite frequent lipid-lowering failure. Emerging evidence links lorlatinib-associated dyslipidemia to coronary events and stroke at median 356 and 301 days, respectively. A propensity-matched analysis demonstrated that lipid-lowering therapy initiation within 30 days was associated with significantly lower 1-year mortality (16.1% vs. 26.4%; HR 0.60). The 2026 ACC/AHA guidelines recommend treating cancer survivors with life expectancy exceeding 2 years per general population standards. Proactive baseline ASCVD risk assessment, early combination lipid-lowering escalation, and systematic cardiovascular monitoring are essential to mitigate atherosclerotic risk in this growing survivor population.